The Mission Report

Rodman & Renshaw

Annual Global Investment Conference

September 8th - 10th, 2013 - Millennium Broadway Hotel, New York, NY


Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services
to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to
institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction
markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of
PIPE and RD financing transactions completed every year since 2005.

Presenting Companies: A-M N-Z


Active Biotech AB (ATVBF)

Active Biotech AB (OTC: ATVBF) is a biotechnology company focused on autoimmune/inflammatory diseases and cancer. The company has three projects in pivotal phase: laquinimod, an orally administered small molecule with unique immunomodulatory properties for treating multiple sclerosis; TASQ for prostate cancer; and ANYARA, which is primarily for the treatment of renal cell cancer. Laquinimod is additionally in Phase II development for Crohn’s and lupus. For more information, visit the company’s Web site at

Advanced Cell Technology, Inc. (ACTC)

Advanced Cell Technology, Inc. (OTCQB: ACTC) is a biotechnology company engaged in applying cellular technology in the field of regenerative medicine. The company applies stem cell-based technologies – both for adult and “embryo safe” human embryonic stem cells – and other proprietary regenerative medicine methods to bring patient-specific therapies from the lab to the patient’s bedside. For more information, visit the company’s Web site at

Aeterna Zentaris, Inc. (AEZS)

Aeterna Zentaris, Inc. (NASDAQ: AEZS) is a specialty biopharmaceutical company with its focus on developing novel treatments in oncology and endocrinology. The company’s pipeline encompasses compounds from drug discovery to regulatory approval. Its lead drug development programs include zoptarelin doxorubicin (AEZS-108), a hybrid molecule composed of synthetic peptide carrier linked to doxorubicin, specifically targeting LHRH receptor expressing tumors; and macimorelin acetate (AEZS-130), which has received FDA orphan drug designation as a diagnostic test for growth hormone deficiency. For more information, visit the company’s Web site at

Agenus, Inc. (AGEN)

Agenus, Inc. (NASDAQ: AGEN) is a biotechnology company engaged in the development of treatments for cancers and infectious diseases. The company’s focus is on immunotherapeutic products based on strong platform technologies, and it has multiple product candidates advancing through the clinic; this includes several product candidates that have advanced into late-stage clinical trials through corporate partners. For more information, visit the company’s Web site at

Agnico Eagle Mines Limited (AEM)

Agnico Eagle Mines Limited (NYSE: AEM) is a long established, Canadian headquartered, gold producer with operations located in Canada, Finland and Mexico, and exploration and development activities in Canada, Finland, Mexico and the United States. Agnico has full exposure to higher gold prices consistent with its policy of no forward gold sales. It has declared a cash dividend for 31 consecutive years. For more information, visit the company’s Web site at

Alabama Graphite Corp. (ABGPF)

Alabama Graphite Corp. (OTC:ABGPF) through its wholly-owned subsidiary, Alabama Graphite Company Inc., is a graphite exploration and development company whose flagship project "The Coosa Graphite Project" in Coosa County, Alabama is located in an area with significant historical production of crystalline flake graphite. The company recently released its initial Canadian Instrument 43-101 resource, prepared by Metals Mining Consultants Inc. of Colorado co-authored by Qualified Persons, Scott Wilson and Stewart Redwood. For more information, visit the company’s Web site at

Alderon Iron Ore Corp. (AXX)

Alderon Iron Ore Corp. (NYSE MKT: AXX) is a leading Canadian iron ore development company with offices in Vancouver, Toronto, Montreal, St. John’s, and Labrador City. Alderon’s team consists of skilled professionals with significant iron ore expertise. The company’s Kami Project – 75% owned by Alderon and 25% owned by Hebei Iron & Steel Group Co. Ltd. – is located in Canada’s premier iron ore district, surrounded by four producing iron ore mines. For more information, visit the company’s Web site at

Allana Potash Corp. (ALLRF)

Allana Potash Corp. (OTCQX: ALLRF) is publicly traded corporation engaged in acquiring and developing international potash assets. The company’s chief focus is on a previously explored potash property located in Ethiopia. The company has secured financial support from two significant strategic investors, IFC and Liberty Metals and Mining Holdings, LLC (a member of the World Bank Group and a subsidiary of Liberty Mutual Group, respectively). For more information, visit the company’s Web site at

Amarantus Bioscience Holdings Inc. (AMBS)

Amarantus Bioscience Holdings Inc. (OTCQB: AMBS) is a development-stage biotechnology company founded in January 2008. The company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, and other human diseases. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. For more information, visit the company’s Web site at

AmpliPhi BioSciences Corp. (APHB)

AmpliPhi BioSciences Corp. (OTC: APHB) is a biotechnology company engaged in developing and commercializing novel bacteriophage-based therapeutics for human and animal applications. AmpliPhi’s product development programs target Gram-negative infections that are often resistant to existing antibiotic treatments. The company was created through the 2011 merger of BioControl Ltd. and Targeted Genetics, Inc. and the subsequent combination with Special Phage Services in 2012. For more information, visit the company’s Web site at

Anavex Life Sciences Corp. (AVXL)

Anavex Life Sciences Corp. (OTCQB: AVXL) is a pharmaceutical company focused on developing novel drug candidates. The company’s ANAVEX 2-73, which is a drug candidate developed to treat Alzheimer’s through disease modification, has completed an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. It has been indicated in preclinical studies that ANAVEX 2-73 demonstrates anti-amnesiac and neuroprotective properties. For more information, visit the company’s Web site at

Andover Mining Corp. (AOX)

Andover Mining Corp. (TSX-V: AOX) is a precious and base metal exploration development company. Headquartered in Vancouver, British Columbia, Canada, Andover Mining has large land holdings in Alaska’s polymetallic-rich Ambler Mineral Belt and in Utah’s historic East Tintic Mining District. The company has added 9,120 additional acres to its land position in the Ambler District. Chief Consolidated Mining Company (83.5% owned by Andover) is exploring and developing the 18,000 acres of mining properties in Utah. For more information, visit the company’s Web site at

Anika Therapeutics, Inc. (ANIK)

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a leader in developing, manufacturing and commercializing therapeutic products for tissue protection, healing and repair. The company’s products are based on hyaluronic acid (HA), which is a naturally occurring, biocompatible polymer found throughout the body. The company’s aim is to provide therapeutic products that go beyond pain relief to protect and restore damaged tissue. For more information, visit the company’s Web site at

Apollo Medical Holdings, Inc. (AMEH)

Apollo Medical Holdings, Inc. (OTCQB: AMEH) is a leader in providing physician-driven integrated healthcare management services. The company’s integrated healthcare delivery platform, which combines hospitalist medicine, critical care medicine, case management and transition management, is comprised of three affiliated and complementary physician groups: ApolloMed Hospitalists, ApolloMed ACO and Maverick Medical Group. ApolloMed endeavors to improve medical outcomes with high quality, cost-efficient care and is dedicated to putting patients first. For more information, visit the company’s Web site at

ARCA biopharma, Inc. (ABIO)

ARCA biopharma, Inc. (NASDAQ: ABIO) is focused on developing genetically targeted therapies for cardiovascular diseases. Gencaro (bucindolol hydrochloride), the company’s lead product candidate, is an investigational, pharmacologically unique beta-blocker and mild vasodilator that is being developed for atrial fibrillation. The company has identified common genetic variations that it believes can predict individual patient response to Gencaro, which gives it the potential to be the first genetically targeted atrial fibrillation prevention treatment. For more information, visit the company’s Web site at

Arch Therapeutics, Inc. (ARTH)

Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device company that is engaged in developing a novel approach for controlling bleeding and fluid loss during surgery and trauma care. The company’s aim is to develop and commercialize products, based on its innovative technology platform, that make surgery and interventional care faster and safer for patients. AC5, the company’s flagship development-stage product candidate, is being designed to elegantly achieve homeostasis in minimally invasive and open surgical procedures. For more information, visit the company’s Web site at

Arno Therapeutics, Inc. (ARNI)

Arno Therapeutics, Inc. (OTCQB: ARNI) is a clinical stage biopharmaceutical company with its focus on developing innovative oncology therapeutics. The company has exclusive global rights to develop and market three innovative anti-cancer compounds, which are currently in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors. For more information, visit the company’s Web site at

Astur Gold Corp. (AST)

Astur Gold Corp. (TSX-V: AST) is focused on developing its 100% owned Salave Gold Project in Asturias, northern Spain, which is one of Western Europe’s largest undeveloped gold deposits. In 2012, the company received approval for an underground mine from the Commission for Environmental Affairs of the Principality of Asturias and is now completing additional requirements for the processing plant, water discharge and tailings licenses. For more information, visit the company’s Web site at

AtheroNova, Inc. (AHRO)

AtheroNova, Inc. (OTCBB: AHRO) is a biotechnology company engaged in discovering, researching, developing and licensing novel compounds to safely reduce or regress atherosclerotic plaque deposits and improve lipid profiles in humans. In addition to AHRO-001, the company’s lead compound, AtheroNova intends to develop multiple applications for its patented and patent-pending therapies in various market sectors that have been linked to atherosclerosis, including cardiovascular disease, stroke, peripheral artery disease, dementia, Alzheimer’s and erectile dysfunction. For more information, visit the company’s Web site at

Atossa Genetics, Inc. (ATOS)

Atossa Genetics, Inc. (NASDAQ: ATOS), known as “The Breast Health Company,” is dedicated to preventing breast cancer through commercializing patented, FDA-designated Class II diagnostic medical devices. The company is also focused on commercializing patented, laboratory-developed tests (LDT) that can detect breast cancer precursors up to eight years sooner than mammography. For more information, visit the company’s Web site at

Axcelis Technologies, Inc. (ACLS)

Axcelis Technologies, Inc. (NASDAQ: ACLS) has been a provider of innovative, high-productivity solutions for the semiconductor industry for more than 35 years. Headquartered in Beverly, Mass., Axcelis is focused on developing enabling process applications through the design, manufacture and complete lifecycle support of ion implantation, which is one of the most critical and enabling steps in the IC manufacturing process. For more information, visit the company’s Web site at

Bacterin International Holdings, Inc. (BONE)

Bacterin International Holdings, Inc. (NYSE MKT: BONE) is a leader in developing pioneering bone graft material and coatings for medical applications. The company’s proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold for promoting bone, subchondral repair and dermal growth. Bacterin’s products are used in various applications, including enhancing fusion in spine surgery, relieving back pain, promoting bone growth in foot and ankle surgery and promoting cranial healing after neurosurgery. For more information, visit the company’s Web site at


BIOLASE, Inc. (NASDAQ: BIOL) is a biomedical company engaged in the development, manufacturing and marketing of innovative dental and medical lasers. The company additionally markets and distributes high-end 2-D and 3-D digital imaging equipment and CAD/CAM intraoral scanners. BIOLASE’s chief products are pioneering dental laser systems and a complete line of dental imaging equipment. Other laser products the company has in development address ophthalmology and other medical and consumer markets. For more information, visit the company’s Web site at

BioLineRx (BLRX)

BioLineRx (NASDAQ: BLRX) is a biopharmaceutical development company focused on building a product portfolio for unmet medical needs as well as products that have advantages over currently available therapies. BioLineRx in-licenses novel compounds – chiefly from academic institutions and biotech companies based in Israel – and then develops them through preclinical and/or clinical stages and partners with pharmaceutical companies for advanced clinical development and/or commercialization. For more information, visit the company’s Web site at

Brazil Minerals, Inc. (BMIX)

Brazil Minerals, Inc. (OTCQB: BMIX) is a diamond and gold producer with resources and assets in Brazil. The company’s mining assets include a 55% ownership in Duas Barras, which is a diamond and gold producing mine, and the company also has exploration projects for vanadium, titanium, iron and gold, as well as a robust pipeline of other sizeable opportunities throughout Brazil. For more information, visit the company’s Web site at

Brigus Gold Corp. (BRD)

Brigus Gold Corp. (NYSE MKT: BRD) is a burgeoning gold producer focused on maximizing shareholder value through a strategy of efficient production, targeted exploration and select acquisitions. The company operates the wholly owned Black Fox Mine and Mill in the Timmins Gold District of Ontario, Canada, and owns the Goldfields Project located near Uranium City, Saskatchewan, Canada, which hosts the Box and Athona gold deposits. Brigus additionally owns the Ixhuatan Project in the state of Chiapas, Mexico. For more information, visit the company’s Web site at

BSD Medical Corporation (BSDM)

BSD Medical Corporation (NASDAQ: BSDM) is engaged in developing, manufacturing, marketing and servicing systems to treat cancer and benign diseases using heat therapy delivery via focused radiofrequency and microwave energy. The company’s product lines include both hyperthermia and ablation treatment systems. BSD has developed extensive intellectual property and multiple products in the market and has established distribution in the U.S., Europe and Asia. For more information, visit the company’s Web site at

Caliber Imaging & Diagnostics, Inc. (LCDX)

Caliber Imaging & Diagnostics, Inc. (OTCBB: LCDX) is a medical technologies company that designs, develops, and markets innovative imaging solutions that shows tissue at the cellular level. It is currently the only company in the world to offer in vivo confocal microscopes designed specifically for imaging skin and other tissue. The company’s Rapid Cell ID technology enables scientists and physicians to characterize intact normal and abnormal cellular architecture that is otherwise invisible to the naked eye. For more information, visit the company’s Web site at

Calpian, Inc. (CLPI)

Calpian, Inc. (OTC: CLPI), through its Indian subsidiary, offers Money-on-Mobile, a prepaid mobile payment solution, to more than 151,000 retail locations in India. With corporate offices in Dallas, Texas, and operating centers in Georgia and New York, Calpian boasts a management team that has more than 70 years of combined payments business experience. Harold Montgomery, the company’s CEO, is recognized as an industry leader. For more information, visit the company’s Web site at

Can-Fite BioPharma (CANFY)

Can-Fite BioPharma (OTC: CANFY) is a biotechnology company with a pipeline of proprietary small molecule drugs to address inflammatory and cancer diseases. The company was founded on the scientific findings of Founder and CEO Pnina Fishman and is focused on developing small molecule orally bioavailable drugs, ligands and the A3 adenosine receptor, which mediates anti-inflammatory and anti-cancer effects and is suggested as a biological predictive marker. For more information, visit the company’s Web site at

Canacol Energy Ltd. (CAAEF)

Canacol Energy Ltd. (OTC PINK: CAAEF) is an international oil and gas company with operations focused onshore in Colombia and Ecuador. The Corporation has interests in 26 exploration and production contracts that consist of proven oil producing assets and a large exploration inventory of conventional and unconventional oil prospects. Canacol's management team has over 60 years cumulative operating history in Colombia and Ecuador. For more information, visit the company’s Web site at

Capstone Therapeutics (CAPS)

Capstone Therapeutics (OTCQB: CAPS) is a biotechnology company dedicated to developing a pipeline of novel therapeutic peptides targeted at helping patients with underserved medical conditions. The company’s focus is on developing and commercializing two product platforms: AZX100 and Apo E Mimetic Peptide Molecule AEM-28 and its analogs. Capstone is headquartered in Tempe, Ariz. For more information, visit the company’s Web site at

Catalyst Pharmaceutical Partners, Inc. (CPRX)

Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) is a specialty pharmaceutical company engaged in developing and commercializing novel prescription drugs that target rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms and Tourette syndrome. Firdapse, the company’s lead candidate, is in the midst of a global, multicenter, pivotal Phase III trial for the treatment of LEMS. Catalyst is additionally developing a vigabatrin analog (designated CPP-115) that is potentially safer and more potent. For more information, visit the company’s Web site at

Cellceutix Corp. (CTIX)

Cellceutix Corp. (OTCBB: CTIX) is an emerging clinical stage biopharmaceutical company with its focus on developing a pipeline of compounds to target areas of unmet medical need. Kevetrin, the company’s flagship compound, is an anticancer drug that has demonstrated the ability in preclinical studies to regulate the p53 pathway and attack drug-resistant cancers. Cellceutix additionally owns the rights to seven other drug compounds. For more information, visit the company’s Web site at

Celsion Corp. (CLSN)

Celsion Corp. (NASDAQ: CLSN) is engaged in developing and commercializing innovative cancer drugs, including tumor-targeting treatments using focused heat energy combined with heat-activated liposomal drug technology. The company has research, license or commercialization agreements with leading institutions including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford. For more information, visit the company’s Web site at

Champions Oncology, Inc. (CSBR)

Champions Oncology, Inc. (OTCBB: CSBR) is focused on developing advanced technologies to enhance the personalized treatment of human cancers. The company was founded by some of the most renowned cancer diagnosis, treatment and research specialists on earth. Utilizing the proprietary Champions Personalized TumorGraft technology, the company provides cancer patients, physicians and researchers with powerful tools to more effectively guide cancer treatments and the development of new cancer drugs. For more information, visit the company’s Web site at

Clean Diesel Technologies, Inc. (CDTI)

Clean Diesel Technologies, Inc. (NASDAQ: CDTI) is a leading vertically integrated worldwide manufacturer and distributor of emissions control systems and products with its focus on the heavy-duty diesel and light-duty vehicle markets. The company utilizes its proprietary patented Mixed Phase Catalyst technology, ARIS selective catalytic reduction, Platinum Plus fuel-borne catalyst and other technologies to provide high-value sustainable solutions for reducing emissions, increasing energy efficiency and lowering the carbon intensity of on- and off-road engine applications. For more information, visit the company’s Web site at

Coeur Mining, Inc. (CDE)

Coeur Mining, Inc. (NYSE: CDE) is the largest primary silver producer based in the U.S. and a growing gold producer. The company produces from its wholly owned operations: the Palmarejo silver-gold mine, located in Mexico; the San Bartolomé silver mine, located in Bolivia; the Rochester silver-gold mine, located in Nevada; and the Kensington gold mine, located in Alaska. Coeur additionally has other mining interests, projects and strategic investment positions. For more information, visit the company’s Web site at

CytoSorbents Corporation (CTSO)

CytoSorbents Corporation (OTCBB: CTSO) is a therapeutic device company focused on critical care. The company uses blood purification to modulate the immune system, with a goal of preventing or treating multiple organ failure in life-threatening illnesses. The company’s flagship product, CytoSorb, is approved in the European Union as a safe and effective extracorporeal cytokine filter designed to reduce the “cytokine storm” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. For more information, visit the company’s Web site at

CytRx Corporation (CYTR)

CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical research and development company that specializes in oncology. The company’s oncology pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), an improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is increasing its pipeline of oncology candidates based on a novel linker platform technology that can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites. For more information, visit the company’s Web site at

DARA BioSciences, Inc. (DARA)

DARA BioSciences, Inc. (NASDAQ: DARA) is a specialty pharmaceutical company dedicated to the commercialization of oncology treatment and oncology supportive care products. DARA holds the exclusive U.S. marketing rights to Soltamox®, a novel oral liquid formulation of tamoxifen citrate, which is widely used in the treatment and prevention of breast cancer. Soltamox is the only FDA approved oral liquid version of tamoxifen citrate available in the United States, offering breast cancer patients a new option for daily compliance. For more information, visit the company’s Web site at

Del Mar Pharmaceuticals Inc. (DMPI)

Del Mar Pharmaceuticals Inc. (OTCBB: DMPI) is developing new drug candidates targeting orphan cancer indications representing market opportunities in the hundreds of millions of dollars in North America and potentially billions of dollars worldwide. In order to accelerate development timelines and reduce technical risk, the company leverages existing clinical and commercial data from a wide range of sources. For more information, visit the company’s Web site at

Direct Insite Corp. (DIRI)

Direct Insite Corp. (OTCBB: DIRI) delivers cloud-based e-invoicing solutions for AP, AR, and payments automation. For nine years, Direct Insite has built a track record in automating some of the most demanding financial environments, including the shared services organizations of Fortune 3000 companies. Today, over 300,000 suppliers and customers use the company’s e-invoicing network across 100 countries (representing more than 35 currencies and 17 languages). For more information, visit the company’s Web site at

Dot Hill Systems Corp. (HILL)

Dot Hill Systems Corp. (NASDAQ: HILL) is a recognized leader in software and hardware solutions for storing, sharing, protecting, and managing data. Leveraging its proprietary Assured family of storage solutions, Dot Hill solves many of today’s most challenging storage problems – helping IT to improve performance, increase availability, simplify operations, and reduce costs. Dot Hill’s solutions combine storage software with the industry’s most flexible and extensive hardware platform to deliver best-in-class SAN storage solutions with Five 9′s of availability. For more information, visit the company’s Web site at

DURECT Corporation (DRRX)

DURECT Corporation (NASDAQ: DRRX) is a specialty pharmaceuticalcompany developing innovative drugs for pain and chronic diseases, with late-stage development programs including TRANSDUR-Sufentanil, REMOXY, POSIDUR, ELADUR. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy, and safety for small molecule and biologic drugs. For more information, visit the company’s Web site at


EDAP TMS SA (NASDAQ: EDAP) is the world leader in therapeutic ultrasound. The company is well positioned on the HIFU market with Ablatherm for the treatment of prostate cancer and in the ESWL market with the Sonolith range for the treatment of urinary tract stones. These two technologies are based on ultra-sound waves but their markets and contexts are distinct, and they therefore require specific marketing strategies. For more information, visit the company’s Web site at

Elite Pharmaceuticals, Inc. (ELTP)

Elite Pharmaceuticals, Inc. (OTCBB: ELTP) is a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled release products, using proprietary technology. The company specializes in the development of oral controlled release products, such as delayed, sustained, targeted, and pulsatile release tablets, pellets, capsules, granules, and powders. The company’s primary focus is in the therapeutic areas of pain management, allergy, cardiovascular, and infection. For more information, visit the company’s Web site at

Entia Biosciences, Inc. (ERGO)

Entia Biosciences, Inc. (OTCQB: ERGO) brings the credibility of biotechnology to the food science and supplementation markets. The company’s growing portfolio of intellectual property currently spans some of the most powerful antioxidants and bio nutrients occurring in nature. They are rapidly becoming a global leader in Nutrigenomics by identifying, scientifically validating, and commercializing solutions that address multi-billion dollar markets for organic health, beauty, and agriculture. For more information, visit the company’s Web site at

Fibrocell Science, Inc. (FCSC)

Fibrocell Science, Inc. (NYSE: FCSC) is an autologous cell therapy company focused on the development of innovative products for aesthetic, medical, and scientific applications. The fibroblast cell plays a key role in the production of collagen and growth factors which support the skin and other soft tissues; therefore, these cells could play a key role in treating many medical conditions. The company has a robust pipeline and clinical programs based on the autologous fibroblast cell, and believes their aesthetic indication is a beachhead for higher value indications. For more information, visit the company’s Web site at

Galena Biopharma, Inc. (GALE)

Galena Biopharma, Inc. (NASDAQ: GALE) is focused on developing and commercializing targeted oncology treatments to address major unmet medical needs and advance cancer care. The company’s peptide vaccine immunotherapies harness the patient’s own immune system to identify and destroy cancer cells. Utilizing peptide immunogens has many clinical advantages, including an excellent safety profile and long-lasting protection through immune system activation and convenient delivery. For more information, visit the company’s Web site at

General Steel Holdings, Inc. (GSI)

General Steel Holdings, Inc. (NYSE: GSI), headquartered in Beijing, China, produces a variety of steel products including rebar, high-speed wire, and spiral-weld pipe. The company has operations in China's Shaanxi and Guangdong provinces, Inner Mongolia Autonomous Region, and Tianjin municipality. The company has seven million metric tons of crude steel production capacity under management. For more information, visit the company’s Web site at

Genesis Biopharma, Inc. (GNBP)

Genesis Biopharma, Inc. (OTCBB: GNBP) is engaged in the development and commercialization of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage IV metastatic melanoma, and is based on a currently available physician-sponsored investigational therapy at the National Cancer Institute, MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute. For more information, visit the company’s Web site at

GeoVax Labs, Inc. (GOVX)

GeoVax Labs, Inc. (OTCQB: GOVX) is a biotechnology company specializing in the creation, development, and commercialization of human vaccines to combat HIV/AIDS. Designed for predominant AIDS virus subtypes using DNA and viral vector technologies, the company’s unique AIDS vaccine technology is designed for use in uninfected people to protect them from AIDS should they be exposed to the HIV-1 virus. GeoVax’s preventive vaccine recently completed Phase 2 safety trials through the US Government sponsored HIV Vaccine Trials Network (HVTN). For more information, visit the company’s Web site at

Helix BioPharma (HBPCF)

Helix BioPharma (OTC: HBPCF) is a biopharmaceutical company actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate, designed for the treatment of inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer, and its Topical Interferon Alpha-2b, designed to treat epidermal lesions. For more information, visit the company's Web site at

Hemispherx Biopharma, Inc. (HEB)

Hemispherx Biopharma, Inc. (NYSE: HEB) is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. For more information, visit the company’s Web site at

iBio, Inc. (IBIO)

iBio, Inc. (NYSE: IBIO) is a leader in the plant-made pharmaceutical field. The company develops and offers pharmaceutical product applications using its iBioLaunch platform. The iBioLaunch platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins, and vaccines. It uses proprietary, transient gene expression in unmodified green plants instead of materials such as chicken eggs, mammalian and insect cells, transgenic plants, and human blood plasma required by other systems, to produce important biologic pharmaceuticals. For more information, visit the company’s Web site at

Ico Therapeutics (ICOTF)

Ico Therapeutics (OTC: ICOTF) is a Vancouver-based re-profiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products: iCo-007, in Phase 2 for the treatment of Diabetic Macular Edema (DME), iCo-008 (Bertilimumab), a product with Phase 2 clinical history to be developed for sight-threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases. For more information, visit the company’s Web site at

Immune Pharmaceuticals, Inc. (EPCTD)

Immune Pharmaceuticals, Inc. (OTCQX: EPCTD) is a company that applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune has just completed a merger with EpiCept Corporation, which combines Immune's antibody therapeutic platform focused on the treatment of inflammatory diseases and cancer with EpiCept's early stage cancer program and its late-stage topical pain product, AmiKet™. For more information, visit the company’s Web site at

Inovio Pharmaceuticals, Inc. (INO)

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused precancers and cancers, is in phase II. For more information, visit the company’s Web site at

InspireMD, Inc. (NSPR)

InspireMD, Inc. (NYSE MKT: NSPR), a leader in embolic protection stents, seeks to utilize its proprietary MGuard technology to make its products the industry standard for embolic protection stents and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. For more information, visit the company’s Web site at

International Stem Cell Corp. (ISCO)

International Stem Cell Corp. (OTCQB:ISCO) is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. For more information, visit the company’s Web site at

Invion Limited (IVIXF)

Invion Limited (OTC: IVIXF) , formerly CBio Limited, is an Australia-based, clinical-stage biotechnology company that focuses on the development of treatments for major opportunities in the inflammatory diseases market including asthma, chronic bronchitis and lupus. Invion is engaged in the business of research, product development and clinical trials of the therapeutic drug XToll, completing Phase I studies with both intravenous and subcutaneous administration, and three intravenous dosing Phase II clinical trials in rheumatoid arthritis (RA), psoriasis and multiple sclerosis. For more information, visit the company’s Web site at

InVivo Therapeutics Holdings Corp. (NVIV)

InVivo Therapeutics Holdings Corp. (OTCBB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005, and in 2011 earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. For more information, visit the company’s Web site at

Kamada Ltd. (KMDA)

Kamada Ltd. (NASDAQ: KMDA) uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. Kamada’s flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. For more information, visit the company’s Web site at

Keryx Biopharmaceuticals, Inc. (KERX)

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Headquartered in New York City, Keryx has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis. For more information, visit the company’s Web site at

La Jolla Pharmaceutical (LJPC)

La Jolla Pharmaceutical (OTCBB: LJPC), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501 is a product candidate for the treatment of hepatorenal syndrome. For more information, visit the company’s Web site at

LabStyle Innovations (DRIO)

LabStyle Innovations (OTCQB: DRIO) is developing and commercializing a patent-pending technology that seeks to bring rapid diagnostic capabilities to consumers in a distinctive and easy-to-use way through the use of smartphones such as iPhones, Androids and other mobile devices. LabStyle’s initial product is Dario™, an integrated medical device and software system addressing the market for diabetic self-monitoring of blood glucose (SMBG), a market which is estimated to exceed $10 billion worldwide. For more information, visit the company’s Web site at

Lightbridge Corp. (LTBR)

Lightbridge Corp. (NASDAQ: LTBR) is a nuclear fuel technology company with a presence both in the United States and abroad. The company designs and develops proprietary nuclear fuels, which can be used with existing plants and new build reactors. Lightbridge also provides consulting services to corporate and government organizations on subjects ranging from site selection to regulatory matters. The company leads its operations from its headquarters in McLean, Virginia. For more information, please visit the company’s website at

Luna Gold Corp. (LGCUF)

Luna Gold Corp. (OTCBB: LGCUF) is a gold mining company dedicated to the acquisition, exploration, development and operation of gold-rich properties in Maranhao, Brazil. Headquartered in Vancouver, British Columbia, the company’s principal project covers approximately 15,5000 hectares and includes 1 mining license and 3 exploration permits. It also holds interest in a 220,000-hectare exploration property in a different part of Brazil. For more information, please visit the company’s website at

Mangegas Corp. (MNGA)

Mangegas Corp. (NASDAQ: MNGA) creates and develops hydrogen-based alternative fuel by gasifying carbon-rich liquids. With a footprint in the United States and abroad, the company produces cylinders of bottled gas that offer an alternative to acetylene for the metalworking industry. The company’s proprietary MagneGas solution and Plasma Arc Flow refineries can be licensed for the processing of liquid waste. For more information, please visit the company’s website at

Mast Therapeutics, Inc. (MSTX)

Mast Therapeutics, Inc. (NYSE MKT: MSTX) is focused on developing therapies for patients with serious and life-threatening diseases. The biopharmaceutical company’s lead product candidate, MST-188, is designed to treat patients with sickle cell disease. The hemorheologic, cytoprotective and anti-inflammatory therapy is currently in phase 3 trials. Headquartered in San Diego, California, the company used to operate as ADVENTRX Pharmaceuticals. For more information, please visit the company’s website at

Max Sound Corp. (MAXD)

Max Sound Corp. (OTCBB: MAXD) is a development stage company that is dedicated to launching innovative audio technology software. The company’s unique products offer enhanced audio without increased file size or bandwidth usage. Its embedded chip solutions are compatible with LCD and plasma DVDs, DVD players, satellite receivers, mobile video devices, and more. Future plans include licensing its technology to industries with audio-dependent initiatives. For more information, please visit the company’s website at

Merus Labs International Inc. (MSLI)

Merus Labs International Inc. (NASDAQ: MSLI) acquires and licenses branded prescription pharmaceutical products throughout the U.S., Canada, and Europe. The specialty pharmaceutical company has products to treat overactive bladder, chronic bronchitis, pneumonia, and more. Its solutions can meet the needs of big wholesalers and distributors, and also work on a smaller scale for physicians, healthcare providers, and especially patients and their caregivers. For more information, please visit the company’s website at

Miller Energy Resources, Inc. (MILL)

Miller Energy Resources, Inc. (NYSE: MILL) is engaged in the discovery, development, and operation of oil and gas wells throughout east Tennessee’s Appalachian region, as well as areas of south-central Alaska. The independent exploration and production company owns hundreds of thousands of acres of land throughout these energies, as well as interests in 193 active oil wells and 191 gas wells. For more information, please visit the company’s website at


For more frequent updates, follow us on Twitter!

Home     About Us     IR Services     Investors     Partners     Market Research     Blog     Contact     Disclaimer

© 2013 Mission Investor Relations. All rights reserved.
3645 Marketplace Blvd.   Suite 130-280   Atlanta, GA 30344   404-941-8975